Multiple sclerosis

Vaccines and MS – are they still effective?

1000 662 Bradley Schussel

During the coronavirus disease 2019 (COVID-19) pandemic, vaccines have been at the forefront of the public consciousness. This is especially true for individuals with multiple sclerosis (MS), as some may…

read more

No negative effects of COVID-19 lockdown on migraine patients treated with CGRP inhibitors

2560 1440 Anna Stelling, PhD

It has been shown that everyday habits, lifestyle and stress can have a substantial influence on migraine frequency.1,2 The COVID-19 pandemic significantly disrupted the everyday life of people around the…

read more

Ageing in multiple sclerosis – what do we know?

2846 1601 Anna Stelling, PhD

“Ageing comes with many issues in multiple sclerosis (MS): progression, comorbidities, cognition problems and response to treatment”, Pierre Duquette (Department of Neuroscience, University of Montreal, Canada), the chair of the…

read more

How to promote remyelination in MS

2846 1601 Anne Carter, MA (Cantab)

Strategies to promote remyelination was a hot topic at this year’s virtual ACTRIMS/ECTRIMS joint meeting, with three expert presenters each addressing a different aspect of the subject, including the role…

read more

Does the microbiome have a role in MS?

2846 1600 Anne Carter, MA (Cantab)

Can the bacteria living in your gut influence multiple sclerosis (MS) susceptibility and risk of relapse? That was the question Emmanuelle Waubant (University of California, San Francisco, USA) posed during…

read more

Is disease-modifying treatment in primary progressive multiple sclerosis effective after all?

1703 2560 Anna Stelling, PhD

Until now, several randomised controlled trials and real-world studies could not show the clinical benefit of disease‑modifying treatments (DMTs) in primary progressive multiple sclerosis (PPMS).1-4 However, some recently published results…

read more

Neurofilament light chain levels as a biomarker in multiple sclerosis

1703 2560 Anna Stelling, PhD

It has been previously shown that the neuronal cytoskeletal protein neurofilament light chain (NfL) is released into the blood and cerebrospinal fluid (CSF) upon neuroaxonal injury.1 Hence it was not…

read more

Do hormonal changes influence MS in women?

2400 1600 Anne Carter, MA (Cantab)

There is a paradox in multiple sclerosis (MS): females appear to be more susceptible to the disease than males, but also have a better long-term prognosis. Could this be due…

read more
Sun, ray of light, forest, trees

Siponimod shows promising long-term efficacy in SPMS patients

1920 1280 Anna Stelling, PhD

While researchers are looking at the potential of stem cells in the treatment of multiple sclerosis (MS), novel, promising immune-modulating therapies are being developed. At this year’s virtual EAN Congress,…

read more

Paediatric multiple sclerosis: Adding to our knowledge

1920 1080 Anne Carter, MA (Cantab)

Data suggest that between 2 and 5% of patients with multiple sclerosis (MS) are under 18 years old,1 yet there is only one approved treatment option in this population.2,3 During…

read more
Brainwork is supported by unrestricted grants from: